Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination for Paediatric Patients With Inflammatory Bowel Diseases
On behalf of the Paediatric IBD Porto Group of ESPGHAN: R.K. Russell, N. Afzal, M. Aloy, J. Amil-Dias, A. Assa, C. Braegger, J. Bronsky, S. Buderus, J. Martin Carpi, N. Croft, L. De Ridder, J.C. Escher, J. Fell, A. Griffits, C. Hauer, I. Hojsak, J.P. Hugot, S. Hussy, K.L. Kolho, S. Koletzko, A. Levine, P. Lionetti, V. Navas, O. Olen, D. Shouval, M. Sladek, H. Uhlig, J. Van Limbergen, P. Van Rheenen, G. Veereman, D. Wilson, F. Ruemmele, A.M. Staiano, D. Turner, E. Wine.
Disclaimer: Although this paper is produced by the Paediatric IBD Porto Group of ESPGHAN, it does not necessarily represent ESPGHAN policy and is not endorsed by ESPGHAN.
Funding: None.
The authors report no conflicts of interest.
ABSTRACT
In this communication, the members of the Porto group (the European Society for Paediatric Gastroenterology, Hepatology and Nutrition [ESPGHAN], inflammatory bowel diseases [IBD] working group) provide the current available evidence regarding vaccination of children and young adolescents with IBD against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our intent is to help provide meaningful answers to the concerns that parents and adolescents may have.
